Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granzyme B as a Biomarker for Sorafenib in HCC
NCT02072486Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2013
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Granzyme B at 35 days and Overall Survival at 6 months. Started Nov 2013; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02072486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072486.